Trevena (TRVN)
(Delayed Data from NSDQ)
$0.39 USD
-0.01 (-3.55%)
Updated Jun 10, 2024 04:00 PM ET
After-Market: $0.41 +0.02 (6.38%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Trevena, Inc. [TRVN]
Reports for Purchase
Showing records 81 - 100 ( 114 total )
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Reported; Phase 2 Results From TRV027 Are Expected In Two Weeks
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
Oliceridine on Track and TRV027 Coming Soon as Trevena Reports 1Q16; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
Let that Filly Run! FDA Allowing Trevena to Push the Dose in Phase 3
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
Breakthrough Designation Has Meaning, Trevena Set Up for Differentiated Success in Phase III; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
Trevena May Change the Game for Acute Heart Failure - TRV027 Data Preview; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
With 4Q Behind Us, 2Q''s Events Are Compelling Opportunities
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
Trevena Reports 4Q15 as it Gears up for Oliceridine Pivotal Trials; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
Breakthrough Therapy a Win for Oliceridine; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
Oliceridine?s Breakthrough Designation Yields Insights into FDA?s Outlook
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Feb. 1This report contains brief updates on the following: SRPT, RGLS, BMRN, CBYL, CLDX, EPRS, LXRX, PCRX, PRTA, PTCT, RPTP, TTPH, RARE, VTAE, ICPT, CERU, FCSC, GBT, TSRO, TRVN, IRWD, MRTX, DNAI, XNCR. These companies are covered in more detail in separate Daily Notes and/or Company Reports.
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
Trevena Begins Enrolling Oliceridine''s Phase 3 Program
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
Supplemental Phase III Safety Study Underway for Oliceridine - Up Next, End of Phase 2 Meeting; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
After a Rough Start, Opportunities Begin to Stand Out
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
Traveling with Trevena Ahead of a Busy 2016; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
Trevena Reports 3Q15 Ahead of Busy 2016; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Trevena, Inc.
Industry: Medical - Biomedical and Genetics
Investor Day Highlights Lead Programs and Provides Broad Path Forward; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H